- About Us ▼
- Products ▼
- Pipeline ▼
- Current Vacancies
- Conditions of Sale ▼
- Contact Us ▼
Caphosol®, a topical oral agent, is a US patented medical device that lubricates the mucosa of the mouth, tongue and oropharynx and helps maintain the integrity of the oral cavity through its mineralizing potential. The distinguishing feature of Caphosol® is its high concentrations of calcium and phosphate ions.
For further information on Caphosol, please visit: www.caphosol.com (under construction).
In the EU, Caphosol® is also indicated as an adjunct to standard oral care in the prevention and treatment of the mucositis that may be caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with amelioration of pain. Caphosol® is also indicated for dryness of the mouth and oropharynx (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent. Caphosol® is a Class I CE marked medical device.
In the US, Caphosol® is indicated as an adjunct to standard oral care in treating oral mucositis caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with an amelioration of pain. Caphosol® is also indicated for dryness of the mouth (hyposalivation) or throat (xerostomia) regardless of the cause or whether the conditions are temporary or permanent. Caphosol® is an unclassified medical device and is marketed under a 510(k) Premarket Notification Application.
If you wish to know more / are eligible / apply, please click here
Please click here to download